<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3390/pathogens8040161</article-id><article-id pub-id-type="publisher-id">pathogens-08-00161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Rates and Correlates of Short Term Virologic Response among Treatment-Na&#x000ef;ve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4005-8605</contrib-id><name><surname>Tadesse</surname><given-names>Birkneh Tilahun</given-names></name><xref ref-type="aff" rid="af1-pathogens-08-00161">1</xref><xref ref-type="aff" rid="af2-pathogens-08-00161">2</xref><xref rid="c1-pathogens-08-00161" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3209-2731</contrib-id><name><surname>Chala</surname><given-names>Adugna</given-names></name><xref ref-type="aff" rid="af3-pathogens-08-00161">3</xref></contrib><contrib contrib-type="author"><name><surname>Mukonzo</surname><given-names>Jackson</given-names></name><xref ref-type="aff" rid="af4-pathogens-08-00161">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8983-2388</contrib-id><name><surname>Chaka</surname><given-names>Tolosssa Eticha</given-names></name><xref ref-type="aff" rid="af5-pathogens-08-00161">5</xref></contrib><contrib contrib-type="author"><name><surname>Tadesse</surname><given-names>Sintayehu</given-names></name><xref ref-type="aff" rid="af3-pathogens-08-00161">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9259-5288</contrib-id><name><surname>Makonnen</surname><given-names>Eyasu</given-names></name><xref ref-type="aff" rid="af3-pathogens-08-00161">3</xref><xref ref-type="aff" rid="af6-pathogens-08-00161">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8157-1037</contrib-id><name><surname>Brumme</surname><given-names>Zabrina L.</given-names></name><xref ref-type="aff" rid="af7-pathogens-08-00161">7</xref><xref ref-type="aff" rid="af8-pathogens-08-00161">8</xref></contrib><contrib contrib-type="author"><name><surname>Brumme</surname><given-names>Chanson J.</given-names></name><xref ref-type="aff" rid="af8-pathogens-08-00161">8</xref><xref ref-type="aff" rid="af9-pathogens-08-00161">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9788-0790</contrib-id><name><surname>Aklillu</surname><given-names>Eleni</given-names></name><xref ref-type="aff" rid="af1-pathogens-08-00161">1</xref></contrib></contrib-group><aff id="af1-pathogens-08-00161"><label>1</label>Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden; <email>eleni.aklillu@ki.se</email></aff><aff id="af2-pathogens-08-00161"><label>2</label>Department of Pediatrics, College of Medicine and Health Sciences, Hawassa University, Hawassa 1560, Ethiopia</aff><aff id="af3-pathogens-08-00161"><label>3</label>Department of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia; <email>adugnadema@gmail.com</email> (A.C.); <email>ssintayehu2010@gmail.com</email> (S.T.); <email>eyasumakonnen@yahoo.com</email> (E.M.)</aff><aff id="af4-pathogens-08-00161"><label>4</label>Department of Pharmacology, College of Health Sciences, Makerere University, Kampala, Uganda; <email>mukojack@yahoo.co.uk</email></aff><aff id="af5-pathogens-08-00161"><label>5</label>Adama General Hospital and Medical College, Adama 84, Ethiopia; <email>tecb2006@gmail.com</email></aff><aff id="af6-pathogens-08-00161"><label>6</label>CDT Africa, College of Health Sciences, Addis Ababa University, Addis Ababa 9086, Ethiopia</aff><aff id="af7-pathogens-08-00161"><label>7</label>Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada; <email>zbrumme@cfenet.ubc.ca</email></aff><aff id="af8-pathogens-08-00161"><label>8</label>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada; <email>cbrumme@cfenet.ubc.ca</email></aff><aff id="af9-pathogens-08-00161"><label>9</label>Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada</aff><author-notes><corresp id="c1-pathogens-08-00161"><label>*</label>Correspondence: <email>birknehtilahun@gmail.com</email>; Tel.: +251-911551807</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>8</volume><issue>4</issue><elocation-id>161</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>There is limited data on virologic outcome and its correlates among HIV-infected children in resource-limited settings. We investigated rate and correlates of virologic outcome among treatment na&#x000ef;ve HIV-infected Ethiopian children initiating cART, and were followed prospectively at baseline, 8, 12, 24 and 48 weeks using plasma viral load, clinical examination, laboratory tests and pretreatment HIV drug resistance (PDR) screening. Virologic outcome was assessed using two endpoints&#x02013;virological suppression defined as having &#x0201c;undetectable&#x0201d; plasma viral load &#x0003c; 150 RNA copies/mL, and rebound defined as viral load &#x02265;150 copies/mL after achieving suppression. Cox Proportional Hazards Regression was employed to assess correlates of outcome. At the end of follow up, virologic outcome was measured for 110 participants. Overall, 94(85.5%) achieved virological suppression, of which 36(38.3%) experienced virologic rebound. At 48 weeks, 9(8.2%) children developed WHO-defined virological treatment failure. Taking tenofovir-containing regimen (Hazard Ratio (HR) 3.1-[95% confidence interval (95%CI) 1.0&#x02013;9.6], <italic>p</italic> = 0.049) and absence of pretreatment HIV drug resistance (HR 11.7-[95%CI 1.3&#x02013;104.2], <italic>p</italic> = 0.028) were independently associated with earlier virologic suppression. In conclusion, PDR and cART regimen type correlate with rate of virologic suppression which was prominent during the first year of cART initiation. However, the impact of viral rebound in 38.3% of the children needs evaluation.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>cART na&#x000ef;ve</kwd><kwd>virologic outcome</kwd><kwd>pretreatment HIV drug resistance</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathogens-08-00161"><title>1. Introduction</title><p>The number of children accessing combination antiretroviral therapy (cART) has increased over the past decade following global initiatives including &#x0201c;test and treat&#x0201d; and the ambitious UNAIDS 90-90&#x02013;90 treatment targets to help end the AIDS epidemic [<xref rid="B1-pathogens-08-00161" ref-type="bibr">1</xref>,<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>]. The 90-90-90 goals, which were originally hoped to be realized by 2020, aim to have 90% of people living with HIV being aware of their diagnosis; 90% of those with diagnosed infection be on sustained antiretroviral treatment, and 90% of those receiving antiretroviral treatment to have virological suppression [<xref rid="B3-pathogens-08-00161" ref-type="bibr">3</xref>]. Though these ambitious goals are critical in decreasing AIDS related morbidity and mortality in resource limited settings, recent data suggest that these targets may possibly be feasible in some settings [<xref rid="B4-pathogens-08-00161" ref-type="bibr">4</xref>], disparities in the ability of individual countries to perform towards the goals remain substantial [<xref rid="B5-pathogens-08-00161" ref-type="bibr">5</xref>,<xref rid="B6-pathogens-08-00161" ref-type="bibr">6</xref>]. Moreover, the global community currently fall very short of the targets: as of 2017, only 52% of children below the age of 14 years were receiving cART [<xref rid="B1-pathogens-08-00161" ref-type="bibr">1</xref>].</p><p>The main goal of long-term cART in HIV infected children is to achieve sustained virological suppression. Virological suppression is modulated by several factors including baseline viral load. In a European cohort of 420 HIV infected infants, virological suppression at 12 months of follow up was achieved in 89% of studied children, where lower baseline viral load and younger age at cART initiation were associated with faster virological suppression [<xref rid="B7-pathogens-08-00161" ref-type="bibr">7</xref>]. However, fewer data exist on the correlates of virologic suppression in resource-limited settings where pediatric antiretroviral treatment options are fewer [<xref rid="B8-pathogens-08-00161" ref-type="bibr">8</xref>,<xref rid="B9-pathogens-08-00161" ref-type="bibr">9</xref>]. Baseline viral load &#x02265; 100,000 copies per mL and delayed virological suppression were also associated with subsequent risk of virological rebound in a large (N = 53,000) study of HIV-infected adults across 20 major HIV treatment centers in France [<xref rid="B10-pathogens-08-00161" ref-type="bibr">10</xref>], but fewer data exist on the correlates and rates of virologic rebound in resource-limited settings. More importantly, data on the prevalence and impact of pretreatment HIV drug resistance mutations on pediatric firstline antiretroviral treatment regimen efficacy are also scarce for resource-limited settings [<xref rid="B11-pathogens-08-00161" ref-type="bibr">11</xref>,<xref rid="B12-pathogens-08-00161" ref-type="bibr">12</xref>,<xref rid="B13-pathogens-08-00161" ref-type="bibr">13</xref>,<xref rid="B14-pathogens-08-00161" ref-type="bibr">14</xref>]. </p><p>In Ethiopia, high rates of virological suppression have been reported among HIV infected adults [<xref rid="B15-pathogens-08-00161" ref-type="bibr">15</xref>,<xref rid="B16-pathogens-08-00161" ref-type="bibr">16</xref>,<xref rid="B17-pathogens-08-00161" ref-type="bibr">17</xref>,<xref rid="B18-pathogens-08-00161" ref-type="bibr">18</xref>] and children [<xref rid="B16-pathogens-08-00161" ref-type="bibr">16</xref>], which are similar to figures reported for the rest of sub Saharan Africa [<xref rid="B19-pathogens-08-00161" ref-type="bibr">19</xref>]. However, increasing trends of acquired HIV drug resistance and treatment failure have also been reported in Ethiopia, at least in adults [<xref rid="B20-pathogens-08-00161" ref-type="bibr">20</xref>,<xref rid="B21-pathogens-08-00161" ref-type="bibr">21</xref>]. Moreover, a study among HIV-infected Ethiopian adults showed that presence of baseline drug resistance mutations was associated with lower rates of virologic suppression at months six and 12 months of cART [<xref rid="B22-pathogens-08-00161" ref-type="bibr">22</xref>]. Though pretreatment HIV drug resistance can substantially influence treatment outcomes, drug resistance information is not used to guide pediatric HIV clinical care in Ethiopia. This is because, in Ethiopia, neither routine plasma viral load monitoring nor HIV drug resistance testing are readily available to guide individualized patient care. Empiric choice of cART is therefore the routine practice. Indeed, the prevalence and impact of HIV drug resistance on firstline antiretroviral treatment outcomes in Ethiopian children living with HIV has not previously been characterized. </p><p>Optimizing pediatric HIV treatment is critical to reduce child mortality and morbidity in resource limited settings, and to ensure that, as a global community, we meet the ambitious UNAIDS and Sustainable Development Goals by 2030. Local data are also crucial to inform policies and programmes for fast-track implementation of pediatric HIV treatment guidelines in such settings. To address the relatively paucity of data in pediatric HIV treatment outcomes in high HIV-burden settings, in particular the impact of baseline factors including pretreatment HIV drug resistance mutations on virological suppression these settings, we report the results of a multicenter prospective cohort study which assessed virological outcomes and associated factors at 8, 12, 24 and 48 weeks of initiation of cART among newly diagnosed HIV infected children attending HIV/AIDS clinics in Ethiopia. </p></sec><sec sec-type="methods" id="sec2-pathogens-08-00161"><title>2. Methods </title><sec id="sec2dot1-pathogens-08-00161" sec-type="subjects"><title>2.1. Study Participants </title><p>The Efavirenz Pediatric Dose Optimization Study (EPDOS) originally enrolled 111 cART na&#x000ef;ve HIV-infected children at seven HIV/AIDS treatment centers across two of the largest administrative regions in Ethiopia: Oromia and Southern Nations Nationalities and Peoples Region (SNNPR), whose combined populations exceed 55 million [<xref rid="B23-pathogens-08-00161" ref-type="bibr">23</xref>]. The centers in Oromia region were: Adama General Hospital, Asela Referral and Teaching Hospital, and Shashemene General Hospital; from SNNPR: Hawassa University Comprehensive Specialized Hospital, Adare General Hospital, Otona Referral Hospital and Arbaminch General Hospital. These regions were selected because of their high HIV prevalence and the large and diverse population, which is generalizable to the whole country. In Ethiopia, the estimated HIV pediatric population is 62,000 (38,000&#x02013;86,000) [<xref rid="B24-pathogens-08-00161" ref-type="bibr">24</xref>].</p><p>Participants were between the ages of 3&#x02013;12 years, were cART na&#x000ef;ve, whose parents/guardians consented to participate in the study and were able and willing to stay in follow up, and who had no acute severe illnesses at enrolment. Since Ethiopia practices the &#x0201c;test and treat&#x0201d; strategy, participants were enrolled within 2&#x02013;4 weeks of HIV diagnosis after the required pretreatment counselling was completed. Children who had tuberculosis and those who had previously been on combination antiretroviral therapy were excluded, though PMTCT exposure was allowable. Note however that PMTCT history was not comprehensively available for study participants. Demographic, clinical and laboratory data were collected at baseline. Plasma viral load (pVL) was determined using the Real Time HIV-1 viral load test (Abbott, Des Plaines, IL, USA) using a 0.2 mL input volume of plasma.</p></sec><sec id="sec2dot2-pathogens-08-00161"><title>2.2. Combination Antiretroviral Therapy</title><p>In accordance with the Ethiopian national guidelines for first line pediatric cART, all children were initiated on a regimen comprising two Nucleoside Reverse Transcriptase Inhibitors (lamivudine plus one of zidovudine, abacavir or tenofovir) (NRTIs) and one Non-nucleoside Reverse Transcriptase Inhibitor [<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>,<xref rid="B25-pathogens-08-00161" ref-type="bibr">25</xref>]. The NNRTI was efavirenz for all the children [<xref rid="B25-pathogens-08-00161" ref-type="bibr">25</xref>]. Prior to initiating cART, all participants received adherence counselling from professional nurse counsellors working in the HIV treatment center. The specific firstline cART regimen was selected by the clinician responsible for the care and follow up of the children. The study team did not have any role in the choice of cART regimen. </p></sec><sec id="sec2dot3-pathogens-08-00161" sec-type="methods"><title>2.3. Data Collection Procedures </title><p>Clinical and laboratory measurements were collected at baseline (study enrollment) and at 8, 12, 24 and 48 weeks post-cART initiation. At baseline, a detailed clinical history, clinical examination and relevant laboratory tests were done. This included a detailed clinical assessment of symptoms, a physical examination, nutritional assessment (history and anthropometrics) and Karnofsky functional scoring. Baseline laboratory tests included plasma viral load (pVL), CD4 count, hemoglobin level, platelet count, and chemistry (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, albumin, and blood urea nitrogen (BUN), Creatinine, and lipid profile levels). All clinical and laboratory tests performed at baseline were repeated at weeks 8, 12, 24 and 48 post-cART. Adherence counselling was also provided to all participants. Adherence was assessed using a composite of pill count, self-report and the visual analogue score (VAS) [<xref rid="B26-pathogens-08-00161" ref-type="bibr">26</xref>]&#x02014;0% means they have taken none; 50% means they have taken half; and 100% means they have taken every single dose. Adherence of &#x0003e;95% was considered &#x0201c;optimal&#x0201d;.</p></sec><sec id="sec2dot4-pathogens-08-00161"><title>2.4. HIV Drug Resistance Testing </title><p>Baseline drug resistance testing was performed using dried blood spots (DBS) or dried plasma spots (DPS) as described in Tadesse et al. [<xref rid="B27-pathogens-08-00161" ref-type="bibr">27</xref>]. Briefly, using a standard &#x000bc;&#x0201d; manual hole punch or a pair of metal forceps, two spots (plasma or blood, as provided) per participant were transferred into sterile tubes for nucleic acid extraction [<xref rid="B28-pathogens-08-00161" ref-type="bibr">28</xref>]. The hole punch was cleaned of residual material between participant cards by punching 10 holes into clean filter paper [<xref rid="B28-pathogens-08-00161" ref-type="bibr">28</xref>]; the forceps were cleaned using bleach. Total nucleic acids were extracted using the NucliSENS easyMAG System according to manufacturer&#x02019;s instructions (BioMerieux, Marcy-l&#x02019;&#x000c9;toile, France). </p><p>HIV Protease and a portion of Reverse Transcriptase (RT) spanning a minimum of codons 1-234 were amplified via an initial Reverse Transcriptase step (Expand Reverse Transcriptase; Roche, Basel, Switzerland) followed by nested PCR (Expand Hifi System; Roche) or alternatively by RT-PCR (using the SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA Polymerase; Invitrogen, MA, USA) followed by nested PCR (using the Expand HiFi System; Roche) [<xref rid="B21-pathogens-08-00161" ref-type="bibr">21</xref>]. Amplification was attempted using up to four oligonucleotide primer sets designed to amplify various HIV-1 group M subtypes: if amplification failed using the primary set, amplification was attempted using the backup sets. If amplification failed again, fresh nucleic acid extracts were prepared from remaining DPS or DBS and amplification was re-attempted as above. Amplicons were visualized on a 1% agarose gel and bulk (directly) sequenced on a 3130xl or 3730xl automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). Chromatograms were analyzed using Sequencher version 5.0.1 (Gene Codes, Ann Arbor, MI, USA) or the automated basecalling software RECall [<xref rid="B29-pathogens-08-00161" ref-type="bibr">29</xref>], where nucleotide mixtures were called if the secondary peak exceeded 25% of the dominant peak <italic>height</italic> (Sequencher) or 17.5% of the dominant peak <italic>area</italic> (RECall).</p><p>However, in contrast to the previous manuscript which utilized the list of mutations for surveillance of transmitted HIV drug resistance defined by the World Health Organization (WHO) 2009 [<xref rid="B30-pathogens-08-00161" ref-type="bibr">30</xref>], drug resistance interpretations in the present study were performed using the Stanford HIVdb algorithm (version 8.8) [<xref rid="B31-pathogens-08-00161" ref-type="bibr">31</xref>]. This is because the present study explicitly assessed the impact of any pretreatment HIV drug resistance on individual-level virologic outcomes, whereas the main goal of the previous study was to characterize the burden of PDR in the pediatric setting, along with the specific mutations commonly observed, at the population level. Participants were classified as having PDR if resistance interpretation with Stanford HIVdb suggested low- to high-level resistance (score &#x02265;15) to one or more ARVs</p></sec><sec id="sec2dot5-pathogens-08-00161"><title>2.5. Virological Outcome Definitions</title><p>As the limit of detection of the Abbott Real Time HIV-1 viral load test is 150 copies/mL for the 0.2 mL starting volume of plasma used for analysis, a pVL &#x0003c; 150 copies HIV RNA/mL was considered &#x0201c;undetectable&#x0201d;. Virological rebound was defined as at least one pVL &#x02265; 150 copies/mL in a participant who had previously achieved a pVL of &#x0003c;150 copies/mL in a preceding follow up visit. Virological treatment failure (VTF) was defined according to the WHO guidelines of two consecutive pVL results &#x02265; 1000 copies per mL, recorded at least 3 months apart, after at least 6 months on cART [<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>] (that is, unlike the definition for virologic rebound, the definition of VTF did not require initial virologic suppression to &#x0003c;150 copies/mL).</p></sec><sec id="sec2dot6-pathogens-08-00161"><title>2.6. Statistical Analysis</title><p>The relationships between baseline demographic, clinical and laboratory variables and achieving virologic outcomes of interest were assessed using univariable and multivariable and Cox proportional hazards regression. Kaplan-Meier survival analysis, with p-values computed using the log-rank test, were also undertaken for select baseline variables to graphically visualize relationships. The following variables were treated as binary or categorical variables, where the following reference categories were used. For sex, the reference category was &#x0201c;male&#x0201d;. Pretreatment drug resistance (PDR), tuberculosis (TB), isoniazid preventive therapy (IPT) and cotrimoxazole preventive therapy (CPT) were also treated as binary variables (&#x0201c;yes&#x0201d; vs. &#x0201c;no&#x0201d;), where &#x0201c;yes&#x0201d; was the reference category. Categorical variables included cART regimen (where abacavir-based regimen was considered the reference category) and WHO clinical staging (where clinical stage I was the reference category). Hazards for continuous variables were defined as follows: &#x02013; age (per year decrement), AST and ALT (per unit/L decrement), Albumin, BUN, Creatinine and bilirubin (per mg/dL decrement), baseline viral load (per log<sub>10</sub> copies/mL decrementCD4 count (per cells/uL increment), hematocrit (per 1% increment), total cholesterol, LDL, HDL, TG, WAZ, HAZ and BAZ (per mg/dL increment). In survival analyses, subjects who were lost to follow up or who died were censored at their last follow up timepoint. Covariates with a <italic>p</italic>-value of &#x0003c;0.2 in univariable analyses were included in the multivariable models. R software package (The R Foundation for Statistical Computing, Vienna, Austria) and GraphPad Prism version 7 (version 7, San Diego, CA, USA) were used for the analysis and presentation of the results. </p></sec><sec id="sec2dot7-pathogens-08-00161"><title>2.7. Ethics Statement</title><p>Ethical approval for this study was obtained from the Institutional Ethics Review Boards of Addis Ababa University, College of Health Sciences, SNNPR Regional Health Bureau, Karolinska Institutet in Stockholm, Simon Fraser University and Providence Health Care/University of British Columbia. The renewed National Research and Ethics Review Committee Ethics certificate is SHE/SM/14.3/0421/1/2019. Blood samples were collected after obtaining written informed consent in accordance with the tenets of the Declaration of Helsinki. For participants &#x02264;12 years, written informed consent was obtained from their parent or guardian, while for participants &#x0003e;12 years of age, consent was obtained from the parent or guardian and assent obtained from the participant. All informed consent documents were provided in the local language.</p></sec></sec><sec sec-type="results" id="sec3-pathogens-08-00161"><title>3. Results</title><sec id="sec3dot1-pathogens-08-00161" sec-type="subjects"><title>3.1. Baseline Characteristics of Study Participants </title><p>A total of 111 participants were recruited for study, for whom 110 (99.1%) had a baseline log<sub>10</sub> pVL measurement (<xref ref-type="fig" rid="pathogens-08-00161-f001">Figure 1</xref>). </p><p>Additional baseline characteristics of cohort participants are detailed in <xref rid="pathogens-08-00161-t001" ref-type="table">Table 1</xref>. The median age of participants was 9 years (interquartile range: 5&#x02013;12 years); the majority (56.8%) were male. The majority of the children, 44 (40%) were asymptomatic at cART initiation while 23 (20.9%), 33 (30%) and 10 (9.1%) were classified as being in WHO clinical stage 2, 3 and 4, respectively. Despite the relatively high prevalence of clinically-apparent symptoms however, participant functional Karnofsky scores (a self-reported measure of functional status that ranges from 0 to 100, where 100 indicates no health complaints), were high: 94 (82.5%) of participants recorded a Karnofsky functional score of 100 points at baseline. Most children, 59 (53.2%) were started on a tenofovir (TDF)/lamivudine (3TC)/efavirenz (EFV) regimen while 37 (33.3%) were initiated on an abacavir/3TC/EFV regimen and 15 (13.5%) were initiated on a zidovudine (AZT)/3TC/EFV regimen. Eighty-one (83.5%) and 34 (30.6%) were also initiated on co-trimoxazole preventive therapy (CPT) and isoniazid preventive therapy (IPT), respectively. The median (Q1&#x02013;Q3) baseline CD4 count was 330 (178&#x02013;741) cells/mL, and the median (Q1&#x02013;Q3) log<sub>10</sub> baseline pVL was 4.2 (3.3&#x02013;4.9) copies/mL. Prior to initiating cART, all participants received optimal adherence counselling by a nurse counsellor. The level of adherence to treatment was reported as being optimal in all children during all follow up visits. </p><p>Of the 51 participants for whom baseline resistance testing was successful, PDR was detected in six (11.8%). All participants with PDR had low- to high-level resistance to one or more ARVs. Specifically, five of the participants with PDR (83%) had intermediate- to high-level resistance efavirenz which may have compromised the efficacy of their initial cART regimen. The remaining participant with study-defined PDR had HIV that harbored the RT E138A mutation that confers low-level resistance to rilpivirine. No NRTI resistance was observed in any of the 51 participants for whom baseline resistance genotyping was successful. </p></sec><sec id="sec3dot2-pathogens-08-00161"><title>3.2. Rates and Correlates of Virological Suppression to Undetectable Levels</title><p>A total of 111 cART na&#x000ef;ve HIV infected children were initially enrolled in the EPDOS cohort [<xref rid="B23-pathogens-08-00161" ref-type="bibr">23</xref>], but one participant did not participate in baseline viral load testing and subsequent follow-up (<xref ref-type="fig" rid="pathogens-08-00161-f001">Figure 1</xref>). Follow up was therefore limited to the remaining 110 (99.1%) of participants. Over the study course, 13 children (11.8%) were either lost to follow up or were transferred out to another center out of the catchment region. An additional three children died: a 13 year boy died at home of unknown cause, and two girls, aged 6 and 10 years, who were initially classified as lost to follow up, were later confirmed to have died when the study team attempted to trace them (<xref ref-type="fig" rid="pathogens-08-00161-f001">Figure 1</xref>). In total, 95 (86.4%) participants successfully completed all 48 weeks of follow up. </p><p>Of the 110 HIV infected treatment na&#x000ef;ve children who entered follow up, 94/110 (85.5%) achieved undetectable viremia, defined as pVL &#x0003c; 150 copies per mL, at some point during the study period. We explored clinical and laboratory correlates of virological suppression to pVL &#x0003c; 150, using Cox proportional Hazards regression. In univariable analyses, no baseline variables were statistically significantly associated with attaining pVL &#x0003c; 150 copies/mL during study follow-up (<xref rid="pathogens-08-00161-t002" ref-type="table">Table 2</xref>). However, a number of variables were weakly associated with attaining pVL &#x0003c; 150 copies/mL at p-values &#x0003c; 0.2. </p><p>Specifically, the following baseline characteristics were identified as protective (that is, they were associated with a greater rate of achieving undetectable viremia in univariate analyses). Each decrease of one integer unit of body-mass-index-for-age Z-score (BAZ) was associated with a 10% increased rate of achieving undetectable viremia (Hazard Ratio (HR) 1.1 [95% CI 0.9&#x02013;1.3], <italic>p</italic> = 0.09. Being on a TDF-containing cART regimen was associated with a 40% higher rate of achieving undetectable viremia (HR 1.4 [95% CI 0.9&#x02013;2.1] compared to participants on other regimen types (<italic>p</italic> = 0.18). The relationship between virological suppression to undetectable levels and NRTI drug type contained in first line cART is also depicted using Kaplan-Meier curves in <xref ref-type="fig" rid="pathogens-08-00161-f002">Figure 2</xref>. Moreover, lacking pre-treatment drug resistance (PDR) was associated with a 2.6-fold increased rate of achieving undetectable viremia (Hazard Ratio 2.6 [95% CI 0.8&#x02013;8.6]) compared to participants with PDR (<italic>p</italic> = 0.12). The relationship between PDR and time to achieving pVL &#x0003c;150 copies/mL is also graphically illustrated in <xref ref-type="fig" rid="pathogens-08-00161-f002">Figure 2</xref>. The following baseline characteristics were identified as &#x0201c;risk&#x0201d; (that is, they were associated with <italic>decreased</italic> rate of achieving undetectable viremia in univariate analyses). Not taking isoniazid preventive therapy (IPT) was associated with 30% decreased rate of achieving virological suppression (HR 0.7 [95% CI 0.5&#x02013;1.2], <italic>p</italic> = 0.19). Similarly, being classified into WHO clinical stage 2 or stage 3 was associated with 30% decreased rate of achieving undetectable viremia (HR 0.8 - [95% CI 0.7&#x02013;1.1]) compared to being classified into stage 1 (<italic>p</italic> = 0.08, data not shown). Each decrease in baseline viral load by one log<sub>10</sub> copies per ml was associated with a 20% decreased rate of achieving undetectable viremia (HR 0.8 - [95% CI 0.7&#x02013;1.1], <italic>p</italic> = 0.13). Virological suppression to undetectable levels stratified by baseline viral load is graphically illustrated using Kaplan-Meier curves in <xref ref-type="fig" rid="pathogens-08-00161-f002">Figure 2</xref>. Each decrease in baseline low density lipoprotein (LDL) by one mg/dl was associated with a 10% shorter time to achieving undetectable viremia (HR 0.9 - [95% CI 0.9&#x02013;1.0], <italic>p</italic> = 0.17). </p><p>A multivariable model was constructed using all baseline parameters with <italic>p</italic>-values of &#x0003c; 0.2 in the univariable analyses, with the exception of body-mass-index-for-age Z-score (BAZ). The latter was excluded to avoid the possibility of collinearity, as both height-for-age Z-score (HAZ) and weight-for-age Z-score (WAZ) were included in the model, and BAZ is a function of weight and height. After adjustment for all baseline factors included in the model, the only variables that remained independently associated with time to virological suppression &#x0003c; 150 copies per mL were pretreatment drug resistance and type of cART regimen were (<xref rid="pathogens-08-00161-t002" ref-type="table">Table 2</xref>). Lacking pretreatment HIV drug resistance was associated with an 12 times higher rate of virologic suppression to undetectable levels compared to having pretreatment HIV drug resistance (HR: 11.1 95% CI: 1.3&#x02013;94.7, <italic>p</italic>-value = 0.028). Being on a TDF based cART regimen was associated with 3.1 times shorter time to virological suppression compared to being on an ABC based regimen (HR: 3.1; 95% confidence interval &#x02013; 95% CI: 1.0&#x02013;9.6; <italic>p</italic>-value = 0.049).</p></sec><sec id="sec3dot3-pathogens-08-00161"><title>3.3. Rates and Correlates of Subsequent Virologic Rebound</title><p>We next assessed rates of virologic rebound defined as registering at least one pVL &#x02265; 150 copies/mL after having first achieved a pVL of &#x0003c; 150 copies/mL; as such, this analysis was restricted to the 94 children who had achieved virological suppression at least once during follow up. Of these 94 children, 36 (38.3%) subsequently experienced virological rebound. Specifically, of these 36 children, 11 (30.6%), who were suppressed at week 8 had a rebound at week 12; another 11 children (30.6%) who had achieved suppression at weeks 8 and/or 12 had rebound at week 24; and, 14 (38.9%) children who had achieved one or more virological suppression at weeks 8, 12 and/or 24 had viral rebound at week 48. The median of the peak viral rebound was 2.2 (Q1&#x02013;Q3: 2.2&#x02013;3.0) log<sub>10</sub> copies/mL.</p><p>We next employed Cox proportional Hazards regression to characterize the relationship between participant clinical and demographic characteristics and risk of virologic rebound. Of note, the variables investigated in the present analysis were those measured at baseline, not at the time of initial virologic suppression. On univariable analysis, a decrease by one year of age was associated with a 10% lower rate of viral rebound (HR 0.9 [95% CI 0.8&#x02013;1.0], <italic>p</italic> = 0.12). Similarly, taking a TDF-containing firstline regimen resulted in a 60% reduction in the hazard of virologcal rebound (HR 0.4 - [95% CI 0.2&#x02013;0.9], <italic>p</italic> = 0.027). The trend of virological rebound stratified by the NRTI drug contained in firstline regimen is depicted using Kaplan-Meier curves (<xref ref-type="fig" rid="pathogens-08-00161-f003">Figure 3</xref>). Not taking CPT was also associated with a 60% reduction in the hazard of virological rebound (HR 0.4 - [95% CI 0.2&#x02013;0.9], <italic>p</italic> = 0.04). On the other hand, being WHO clinical stage 4 increased the hazard of virological suppression by 4-fold (HR 4.0 - [95% CI 1.1&#x02013;14.3], <italic>p</italic> = 0.036). The relationship between CPT status and WHO clinical stage with the trend of virological rebound is described using Kaplan-Meier curves in <xref ref-type="fig" rid="pathogens-08-00161-f003">Figure 3</xref>. Not taking IPT also increased the risk of virological rebound by 1.7-fold (HR 1.7 - [95% CI 0.8&#x02013;3.6], <italic>p</italic> = 0.18) (<xref rid="pathogens-08-00161-t003" ref-type="table">Table 3</xref>).</p><p>A multivariable cox proportional hazards model was constructed using all the variables with p-value &#x0003c; 0.2. After controlling for confounders, all the covariates did not reach statistical significance expect WHO clinical stage which showed a weak association. Specifically, being classified as WHO clinical stage 4 disease resulted in a 3.6 times increased hazard of virologic rebound (HR 3.6 - [95% CI 0.7&#x02013;18.8], <italic>p</italic> = 0.13) (<xref rid="pathogens-08-00161-t003" ref-type="table">Table 3</xref>).</p><p>Of note, of the 36 children who experienced viral rebound following initial suppression according to the above definition, 30 (83.3%) registered only a single pVL result &#x02265; 150 copies per mL after which they later re-achieved virological suppression to &#x0003c; 150 copies/mL. The remaining 6 children (16.7%) never re-achieved suppression, and fulfilled the WHO definition of virological treatment failure (VTF), defined as two consecutive pVL results &#x02265; 1000 copies per mL, recorded at least 3 months apart, after at least 6 months on cART [<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>]. Indeed, the end of the follow up period, 9 of the original 110 study participants (8.2%) had fulfilled the definition of VTF according to the WHO guidelines: these included the latter 6 participants as well as three additional children who never achieved pVL suppression &#x0003c; 150 copies/mL at any point during study follow up.</p></sec></sec><sec sec-type="discussion" id="sec4-pathogens-08-00161"><title>4. Discussion</title><p>Achieving sustained virologic suppression following initiation of cART is critical to ensure reduction in mortality and morbidity of HIV infected children, but limited data exist on the rates and correlates of virologic response among HIV-infected children in East and Southern Africa (ESA). Several factors could affect virological suppression among HIV infected children including effective cART regimens, optimal adherence to treatment and other clinical-laboratory predictors [<xref rid="B32-pathogens-08-00161" ref-type="bibr">32</xref>]. To our knowledge, this the first prospective study of cART na&#x000ef;ve HIV infected children in Ethiopia that sought to evaluate the association between baseline demographic and clinical variables, including the presence of primary HIV drug resistance, with virologic outcomes in the first year of cART initiation. Moreover, in Ethiopia, there is no disaggregated national pediatric data on the rate of sustained virological suppression among HIV infected children who initiated cART (that is, the statistic represented by the third &#x0201c;90&#x0201d; of the UNAIDS 90-90-90 goal) [<xref rid="B5-pathogens-08-00161" ref-type="bibr">5</xref>]. Only an aggregate estimate of 86% virological suppression in 2016 has been reported, which is higher than the ESA regional average of 52% [<xref rid="B33-pathogens-08-00161" ref-type="bibr">33</xref>,<xref rid="B34-pathogens-08-00161" ref-type="bibr">34</xref>,<xref rid="B35-pathogens-08-00161" ref-type="bibr">35</xref>]. The current study revealed high initial rates of virological suppression - 85.5% of participants achieved pVL &#x0003c;150 copies/mL at some point during study follow up - a rate that is comparable to reports by other studies [<xref rid="B8-pathogens-08-00161" ref-type="bibr">8</xref>,<xref rid="B9-pathogens-08-00161" ref-type="bibr">9</xref>,<xref rid="B17-pathogens-08-00161" ref-type="bibr">17</xref>,<xref rid="B18-pathogens-08-00161" ref-type="bibr">18</xref>]. Our study further revealed that, after adjusting for other baseline factors, the presence of PDR and the use of abacavir-containing first-line cART regimen were associated with lower rates of virologic suppression.</p><p>Even though a high proportion of children initially achieved virological suppression, a substantial proportion (38.3%) subsequently registered at least one pVL &#x02265; 150 copies per mL, a rate that is similar to a study from South Africa [<xref rid="B35-pathogens-08-00161" ref-type="bibr">35</xref>]. Those who were classified as being WHO clinical stage 4 had an increased hazard of virologic rebound. Promisingly however, the majority (~80%) of participants who experienced viral rebound went on to re-achieve pVL suppression, suggesting that most were transient viral &#x0201c;blips&#x0201d; rather than an indication of virologic treatment failure (VTF). Indeed, VTF rates were relatively low: only nine of the original 110 study participants (8.2%) fulfilled the WHO definition of VTF at the end of the study period. Taken together, the findings show that newly diagnosed HIV infected children who are started on standard cART regimes, as recommended by the WHO guidelines [<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>], generally do well virologically at 48 weeks of treatment.</p><p>The impact of PDR on virologic outcomes among newly-diagnosed HIV infected children is not well established in resource-limited settings [<xref rid="B22-pathogens-08-00161" ref-type="bibr">22</xref>,<xref rid="B36-pathogens-08-00161" ref-type="bibr">36</xref>,<xref rid="B37-pathogens-08-00161" ref-type="bibr">37</xref>,<xref rid="B38-pathogens-08-00161" ref-type="bibr">38</xref>,<xref rid="B39-pathogens-08-00161" ref-type="bibr">39</xref>]. In theory, PDR could compromise the efficacy of first-line cART regimens, thereby reducing rates of virological suppression and increasing subsequent rates of virological treatment failure. However, previous studied have reported conflicting results. Several African and multinational studies reported a positive association between PDR and virologic suppression while other studies and in contrast to other African and Asian studies reported the lack of any association between PDR and virological suppression [<xref rid="B39-pathogens-08-00161" ref-type="bibr">39</xref>,<xref rid="B40-pathogens-08-00161" ref-type="bibr">40</xref>]. Our study showed that, after adjusting for other baseline factors, presence of any PDR was associated with reduced rates of virological suppression.</p><p>The difference in virological suppression between HIV infected children with PDR and those without is significant after the third month of cART indicating that more children with PDR continue to have high viral load. Interestingly our result indicates no significant association of PDR with risk of viral rebound. Despite several studies which reported the relevance of baseline viral load as a predictor of virologic outcome [<xref rid="B10-pathogens-08-00161" ref-type="bibr">10</xref>,<xref rid="B41-pathogens-08-00161" ref-type="bibr">41</xref>,<xref rid="B42-pathogens-08-00161" ref-type="bibr">42</xref>], our study demonstrated no association between the level of baseline viral load and virologic response.</p><p>Antiretroviral regimens types have differing safety and efficacy outcomes among HIV infected children. All the children who were included in the current cohort were started on an efavirenz based cART regimen based on the WHO 2016 consolidated guideline [<xref rid="B2-pathogens-08-00161" ref-type="bibr">2</xref>], which limited our ability to compare the impact of NNRTI drug types on virological outcomes. All children received lamivudine as one component of the NRTI backbone, therefore regimens only differed in terms of the second NRTI prescribed. A tenofovir based regimen was found to be associated with earlier virological suppression as compared to an abacavir based cART regimen, while no statistically significant difference was observed for zidovudine based regimens. However, studies have shown comparable antiviral activity between tenofovir/lamivudine and abacavir/lamivudine combined with dolutegravir and abacavir/lamivudine versus tenofovir/ emtricitabine [<xref rid="B43-pathogens-08-00161" ref-type="bibr">43</xref>,<xref rid="B44-pathogens-08-00161" ref-type="bibr">44</xref>,<xref rid="B45-pathogens-08-00161" ref-type="bibr">45</xref>]. The similar findings in previous reports could be because of the differing third agent in the cART combination and warrants more investigation.</p><p>Our study has several strengths including the prospective follow up ensuring higher data quality, and assessment of pretreatment HIV drug resistance. It also assessed a wide range of clinical and laboratory parameters to determine their association with virologic outcome. However, the small sample size in certain subgroups could have limited the statistical power of the study. Nearly 12% of the participants were transferred out or were lost to follow up further decreasing the sample size for the last follow up. The low success rate of HIV drug resistance genotyping might decrease the power to find any associations. However, despite this limitation, participants in whom genotyping was successful versus not did not differ with respect to their baseline characteristics except albumin levels. Moreover, anyone with PDR was treated as &#x0201c;resistant&#x0201d; regardless of whether the mutations conferred decreased susceptibility to the regimen they were on.</p><p>In conclusion, the study showed that a high proportion of HIV infected children achieve virological suppression at 48 weeks of cART. Pretreatment HIV drug resistance is associated with delayed virological suppression while a tenofovir based cART regimen is independently associated with earlier virological suppression during the first year of treatment. Our study also showed that there is a high prevalence of viral rebound, although these episodes were primarily transient virological &#x0201c;blips&#x0201d; and generally did not precede virological treatment failure. Our findings indicate the need for individualized patient care decisions based on presence of drug resistance mutations at baseline. Furthermore, it calls for more studies with larger sample size to understand the relationship between PDR, treatment regimen and virologic response in pediatric populations.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank children and parents who participated in the study and all the health professionals who were involved in the follow up of the children. We thank Olivia Tsai, Hope Lapointe, Bemuluyigza Baraki and Aniqa Shahid for assistance with HIV drug resistance genotyping.</p></ack><notes><title>Author Contributions</title><p>Conceptualization, B.T.T., A.C., E.M., and E.A.; methodology, B.T.T., A.C., J.M., T.E.C., E.M.; Z.L.B., C.J.B., E.A.; software, B.T.T., Z.L.B., E.A., C.J.B.; validation, B.T.T., J.M., E.M., Z.L.B., C.J.B., E.A., A.C., T.E.C., S.T.; formal analysis, B.T.T., Z.L.B., C.J.B., and E.A.; investigation, B.T.T., A.C., E.A., E.M., J.M., and S.T.; data curation, B.T.T., A.C., T.E.C., S.T., E.M., and E.A.; visualization, B.T.T., E.A., Z.L.B., and C.J.B.; supervision, E.A., E.M., Z.L.B., and C.J.B.; project administration, B.T.T., A.C., T.E.C., E.M., and E.A.; funding acquisition, E.A., and Z.L.B.; resources, E.A., Z.L.B., C.J.B.; writing&#x02014;original draft preparation, B.T.T., E.A., C.J.B., and Z.L.B.; and writing&#x02014;review and editing, B.T.T., A.C., T.E.C., S.T., J.M., E.M., Z.L.B., C.J.B., and E.A.</p></notes><notes><title>Funding</title><p>This research was funded by Swedish Research Council (Vetenskapsr&#x000e5;det) grant number: 2015-03295. This research was also funded in part by the Canadian Institutes for Health Research (PJT-148621 to ZLB). ZLB is supported by a Scholar Award from the Michael Smith Foundation for Health Research.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pathogens-08-00161"><label>1.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>Progress towards the 90-90-90 Targets</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.unaids.org/2018">http://aidsinfo.unaids.org/ 2018</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-29">(accessed on 29 May 2019)</date-in-citation></element-citation></ref><ref id="B2-pathogens-08-00161"><label>2.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection&#x02014;Recommendations for a Public Health Approach&#x02014;Second Edition</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/hiv/pub/arv/arv-2016/en/2016">https://www.who.int/hiv/pub/arv/arv-2016/en/ 2016</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-28">(accessed on 28 May 2019)</date-in-citation></element-citation></ref><ref id="B3-pathogens-08-00161"><label>3.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic</article-title><year>2017</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.unaids.org/en/resources/909090">https://www.unaids.org/en/resources/909090</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-29">(accessed on 29 May 2019)</date-in-citation></element-citation></ref><ref id="B4-pathogens-08-00161"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boerma</surname><given-names>R.</given-names></name><name><surname>Schellekens</surname><given-names>O.</given-names></name><name><surname>Rinke de Wit</surname><given-names>T.F.</given-names></name><name><surname>Wit</surname><given-names>F.W.</given-names></name><name><surname>van der Borght</surname><given-names>S.</given-names></name><name><surname>Rijckborst</surname><given-names>H.</given-names></name><name><surname>Chukwumah</surname><given-names>P.</given-names></name><name><surname>Schilthuis</surname><given-names>H.</given-names></name></person-group><article-title>Reaching 90-90-90: Outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa</article-title><source>Antivir. Ther.</source><year>2019</year><pub-id pub-id-type="doi">10.3851/IMP3311</pub-id><?supplied-pmid 31017125?><pub-id pub-id-type="pmid">31017125</pub-id></element-citation></ref><ref id="B5-pathogens-08-00161"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>L.E.</given-names></name><name><surname>Nkoke</surname><given-names>C.</given-names></name><name><surname>Noubiap</surname><given-names>J.J.N.</given-names></name></person-group><article-title>UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on &#x0201c;Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades&#x0201d;</article-title><source>BMJ Glob. Health</source><year>2017</year><volume>2</volume><fpage>e000227</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2016-000227</pub-id><?supplied-pmid 28589026?><pub-id pub-id-type="pmid">28589026</pub-id></element-citation></ref><ref id="B6-pathogens-08-00161"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>J.</given-names></name><name><surname>Raymond</surname><given-names>A.</given-names></name><name><surname>Pozniak</surname><given-names>A.</given-names></name><name><surname>Vernazza</surname><given-names>P.</given-names></name><name><surname>Kohler</surname><given-names>P.</given-names></name><name><surname>Hill</surname><given-names>A.</given-names></name></person-group><article-title>Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades</article-title><source>BMJ Glob. Health</source><year>2016</year><volume>1</volume><fpage>e000010</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2015-000010</pub-id></element-citation></ref><ref id="B7-pathogens-08-00161"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>M.K.</given-names></name><name><surname>Goodall</surname><given-names>R.</given-names></name><name><surname>Judd</surname><given-names>A.</given-names></name><name><surname>Klein</surname><given-names>N.</given-names></name><name><surname>Chiappini</surname><given-names>E.</given-names></name><name><surname>Klimkait</surname><given-names>T.</given-names></name><name><surname>Ngo-Giang-Huong</surname><given-names>N.</given-names></name><name><surname>Palma</surname><given-names>P.</given-names></name><name><surname>Rossi</surname><given-names>P.</given-names></name><name><surname>Thorne</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>1155</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">30741823</pub-id></element-citation></ref><ref id="B8-pathogens-08-00161"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekaran</surname><given-names>P.</given-names></name><name><surname>Shet</surname><given-names>A.</given-names></name><name><surname>Srinivasan</surname><given-names>R.</given-names></name><name><surname>Sanjeeva</surname><given-names>G.N.</given-names></name><name><surname>Subramanyan</surname><given-names>S.</given-names></name><name><surname>Sunderesan</surname><given-names>S.</given-names></name><name><surname>Ramesh</surname><given-names>K.</given-names></name><name><surname>Gopalan</surname><given-names>B.</given-names></name><name><surname>Suresh</surname><given-names>E.</given-names></name><name><surname>Poornagangadevi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Long-term virological outcome in children receiving first-line antiretroviral therapy</article-title><source>AIDS Res. Ther.</source><year>2018</year><volume>15</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12981-018-0208-9</pub-id><?supplied-pmid 30477526?><pub-id pub-id-type="pmid">30477526</pub-id></element-citation></ref><ref id="B9-pathogens-08-00161"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ateba Ndongo</surname><given-names>F.</given-names></name><name><surname>Texier</surname><given-names>G.</given-names></name><name><surname>Ida Penda</surname><given-names>C.</given-names></name><name><surname>Tejiokem</surname><given-names>M.C.</given-names></name><name><surname>Tetang Ndiang</surname><given-names>S.</given-names></name><name><surname>Ndongo</surname><given-names>J.A.</given-names></name><name><surname>Guemkam</surname><given-names>G.</given-names></name><name><surname>Sofeu</surname><given-names>C.L.</given-names></name><name><surname>Kfutwah</surname><given-names>A.</given-names></name><name><surname>Faye</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Virologic Response to Early Antiretroviral Therapy in HIV-infected Infants: Evaluation After 2 Years of Treatment in the Pediacam Study, Cameroon</article-title><source>Pediatr. Infect. Dis. J.</source><year>2018</year><volume>37</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001745</pub-id><?supplied-pmid 28841582?><pub-id pub-id-type="pmid">28841582</pub-id></element-citation></ref><ref id="B10-pathogens-08-00161"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffi</surname><given-names>F.</given-names></name><name><surname>Hanf</surname><given-names>M.</given-names></name><name><surname>Ferry</surname><given-names>T.</given-names></name><name><surname>Khatchatourian</surname><given-names>L.</given-names></name><name><surname>Joly</surname><given-names>V.</given-names></name><name><surname>Pugliese</surname><given-names>P.</given-names></name><name><surname>Katlama</surname><given-names>C.</given-names></name><name><surname>Robineau</surname><given-names>O.</given-names></name><name><surname>Chirouze</surname><given-names>C.</given-names></name><name><surname>Jacomet</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>72</volume><fpage>3425</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx300</pub-id><?supplied-pmid 28961719?><pub-id pub-id-type="pmid">28961719</pub-id></element-citation></ref><ref id="B11-pathogens-08-00161"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamers</surname><given-names>R.L.</given-names></name><name><surname>Schuurman</surname><given-names>R.</given-names></name><name><surname>Sigaloff</surname><given-names>K.C.</given-names></name><name><surname>Wallis</surname><given-names>C.L.</given-names></name><name><surname>Kityo</surname><given-names>C.</given-names></name><name><surname>Siwale</surname><given-names>M.</given-names></name><name><surname>Mandaliya</surname><given-names>K.</given-names></name><name><surname>Ive</surname><given-names>P.</given-names></name><name><surname>Botes</surname><given-names>M.E.</given-names></name><name><surname>Wellington</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study</article-title><source>Lancet Infect. Dis.</source><year>2012</year><volume>12</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(11)70255-9</pub-id><pub-id pub-id-type="pmid">22036233</pub-id></element-citation></ref><ref id="B12-pathogens-08-00161"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittkop</surname><given-names>L.</given-names></name><name><surname>Gunthard</surname><given-names>H.F.</given-names></name><name><surname>de Wolf</surname><given-names>F.</given-names></name><name><surname>Dunn</surname><given-names>D.</given-names></name><name><surname>Cozzi-Lepri</surname><given-names>A.</given-names></name><name><surname>de Luca</surname><given-names>A.</given-names></name><name><surname>Kucherer</surname><given-names>C.</given-names></name><name><surname>Obel</surname><given-names>N.</given-names></name><name><surname>von Wyl</surname><given-names>V.</given-names></name><name><surname>Masquelier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study</article-title><source>Lancet Infect. Dis.</source><year>2011</year><volume>11</volume><fpage>363</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(11)70032-9</pub-id><pub-id pub-id-type="pmid">21354861</pub-id></element-citation></ref><ref id="B13-pathogens-08-00161"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas Sanchez</surname><given-names>P.</given-names></name><name><surname>Holguin</surname><given-names>A.</given-names></name></person-group><article-title>Drug resistance in the HIV-1-infected paediatric population worldwide: A systematic review</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>2032</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1093/jac/dku104</pub-id><pub-id pub-id-type="pmid">24788658</pub-id></element-citation></ref><ref id="B14-pathogens-08-00161"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLeod</surname><given-names>I.J.</given-names></name><name><surname>Rowley</surname><given-names>C.F.</given-names></name><name><surname>Thior</surname><given-names>I.</given-names></name><name><surname>Wester</surname><given-names>C.</given-names></name><name><surname>Makhema</surname><given-names>J.</given-names></name><name><surname>Essex</surname><given-names>M.</given-names></name><name><surname>Lockman</surname><given-names>S.</given-names></name></person-group><article-title>Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART</article-title><source>J. Clin. Virol.</source><year>2010</year><volume>48</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2010.03.017</pub-id><?supplied-pmid 20427228?><pub-id pub-id-type="pmid">20427228</pub-id></element-citation></ref><ref id="B15-pathogens-08-00161"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekuria</surname><given-names>L.A.</given-names></name><name><surname>Nieuwkerk</surname><given-names>P.T.</given-names></name><name><surname>Yalew</surname><given-names>A.W.</given-names></name><name><surname>Sprangers</surname><given-names>M.A.</given-names></name><name><surname>Prins</surname><given-names>J.M.</given-names></name></person-group><article-title>High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa, Ethiopia</article-title><source>Antivir. Ther.</source><year>2016</year><volume>21</volume><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.3851/IMP3020</pub-id><?supplied-pmid 26731316?><pub-id pub-id-type="pmid">26731316</pub-id></element-citation></ref><ref id="B16-pathogens-08-00161"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulu</surname><given-names>A.</given-names></name><name><surname>Liebert</surname><given-names>U.G.</given-names></name><name><surname>Maier</surname><given-names>M.</given-names></name></person-group><article-title>Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children</article-title><source>BMC Infect. Dis.</source><year>2014</year><volume>14</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-14-28</pub-id><?supplied-pmid 24422906?><pub-id pub-id-type="pmid">24422906</pub-id></element-citation></ref><ref id="B17-pathogens-08-00161"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habtewold</surname><given-names>A.</given-names></name><name><surname>Makonnen</surname><given-names>E.</given-names></name><name><surname>Amogne</surname><given-names>W.</given-names></name><name><surname>Yimer</surname><given-names>G.</given-names></name><name><surname>Aderaye</surname><given-names>G.</given-names></name><name><surname>Bertilsson</surname><given-names>L.</given-names></name><name><surname>Burhenne</surname><given-names>J.</given-names></name><name><surname>Aklillu</surname><given-names>E.</given-names></name></person-group><article-title>Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study</article-title><source>Pharmacogenomics</source><year>2015</year><volume>16</volume><fpage>1047</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.2217/pgs.15.35</pub-id><?supplied-pmid 25831219?><pub-id pub-id-type="pmid">25831219</pub-id></element-citation></ref><ref id="B18-pathogens-08-00161"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amogne</surname><given-names>W.</given-names></name><name><surname>Aderaye</surname><given-names>G.</given-names></name><name><surname>Habtewold</surname><given-names>A.</given-names></name><name><surname>Yimer</surname><given-names>G.</given-names></name><name><surname>Makonnen</surname><given-names>E.</given-names></name><name><surname>Worku</surname><given-names>A.</given-names></name><name><surname>Sonnerborg</surname><given-names>A.</given-names></name><name><surname>Aklillu</surname><given-names>E.</given-names></name><name><surname>Lindquist</surname><given-names>L.</given-names></name></person-group><article-title>Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts &#x0003c;200 Cells/muL: TB-HAART Study, a Randomized Clinical Trial</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0122587</elocation-id><pub-id pub-id-type="pmid">25966339</pub-id></element-citation></ref><ref id="B19-pathogens-08-00161"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taieb</surname><given-names>F.</given-names></name><name><surname>Madec</surname><given-names>Y.</given-names></name><name><surname>Cournil</surname><given-names>A.</given-names></name><name><surname>Delaporte</surname><given-names>E.</given-names></name></person-group><article-title>Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0174767</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0174767</pub-id><?supplied-pmid 28426819?><pub-id pub-id-type="pmid">28426819</pub-id></element-citation></ref><ref id="B20-pathogens-08-00161"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulu</surname><given-names>A.</given-names></name><name><surname>Maier</surname><given-names>M.</given-names></name><name><surname>Liebert</surname><given-names>U.G.</given-names></name></person-group><article-title>Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0186619</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0186619</pub-id><pub-id pub-id-type="pmid">29049402</pub-id></element-citation></ref><ref id="B21-pathogens-08-00161"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadesse</surname><given-names>B.T.</given-names></name><name><surname>Kinloch</surname><given-names>N.N.</given-names></name><name><surname>Baraki</surname><given-names>B.</given-names></name><name><surname>Lapointe</surname><given-names>H.R.</given-names></name><name><surname>Cobarrubias</surname><given-names>K.D.</given-names></name><name><surname>Brockman</surname><given-names>M.A.</given-names></name><name><surname>Brumme</surname><given-names>C.J.</given-names></name><name><surname>Foster</surname><given-names>B.A.</given-names></name><name><surname>Jerene</surname><given-names>D.</given-names></name><name><surname>Makonnen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3390/v10020060</pub-id></element-citation></ref><ref id="B22-pathogens-08-00161"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telele</surname><given-names>N.F.</given-names></name><name><surname>Kalu</surname><given-names>A.W.</given-names></name><name><surname>Gebre-Selassie</surname><given-names>S.</given-names></name><name><surname>Fekade</surname><given-names>D.</given-names></name><name><surname>Abdurahman</surname><given-names>S.</given-names></name><name><surname>Marrone</surname><given-names>G.</given-names></name><name><surname>Neogi</surname><given-names>U.</given-names></name><name><surname>Tegbaru</surname><given-names>B.</given-names></name><name><surname>Sonnerborg</surname><given-names>A.</given-names></name></person-group><article-title>Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: A comparison of Sanger and high-throughput sequencing</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>7556</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-25888-6</pub-id><pub-id pub-id-type="pmid">29765082</pub-id></element-citation></ref><ref id="B23-pathogens-08-00161"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadesse</surname><given-names>B.T.</given-names></name><name><surname>Foster</surname><given-names>B.A.</given-names></name><name><surname>Chala</surname><given-names>A.</given-names></name><name><surname>Chaka</surname><given-names>T.E.</given-names></name><name><surname>Bizuayehu</surname><given-names>T.</given-names></name><name><surname>Ayalew</surname><given-names>F.</given-names></name><name><surname>Getahun</surname><given-names>H.M.</given-names></name><name><surname>Tadesse</surname><given-names>S.</given-names></name><name><surname>Jerene</surname><given-names>D.</given-names></name><name><surname>Makonnen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>HIV and cART-Associated Dyslipidemia Among HIV-Infected Children</article-title><source>J. Clin. Med.</source><year>2019</year><volume>8</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8040430</pub-id></element-citation></ref><ref id="B24-pathogens-08-00161"><label>24.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>Ethiopia: Country Factsheets</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.unaids.org/en/regionscountries/countries/ethiopia2017">https://www.unaids.org/en/regionscountries/countries/ethiopia 2017</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-06-20">(accessed on 20 June 2019)</date-in-citation></element-citation></ref><ref id="B25-pathogens-08-00161"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>EFMOH: Ministry of Health Federal Democratic Republic of Ethiopia</collab></person-group><source>National Guidelines for Comprehensive HIV Prevention, Care and Treatment</source><publisher-name>Ethiopian Ministry of Health</publisher-name><publisher-loc>Addis Ababa, Ethiopia</publisher-loc><year>2016</year></element-citation></ref><ref id="B26-pathogens-08-00161"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amico</surname><given-names>K.R.</given-names></name><name><surname>Fisher</surname><given-names>W.A.</given-names></name><name><surname>Cornman</surname><given-names>D.H.</given-names></name><name><surname>Shuper</surname><given-names>P.A.</given-names></name><name><surname>Redding</surname><given-names>C.G.</given-names></name><name><surname>Konkle-Parker</surname><given-names>D.J.</given-names></name><name><surname>Barta</surname><given-names>W.</given-names></name><name><surname>Fisher</surname><given-names>J.D.</given-names></name></person-group><article-title>Visual analog scale of ART adherence: Association with 3-day self-report and adherence barriers</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2006</year><volume>42</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000225020.73760.c2</pub-id><?supplied-pmid 16810111?><pub-id pub-id-type="pmid">16810111</pub-id></element-citation></ref><ref id="B27-pathogens-08-00161"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadesse</surname><given-names>B.T.</given-names></name><name><surname>Tsai</surname><given-names>O.</given-names></name><name><surname>Chala</surname><given-names>A.</given-names></name><name><surname>Chaka</surname><given-names>T.E.</given-names></name><name><surname>Eromo</surname><given-names>T.</given-names></name><name><surname>Lapointe</surname><given-names>H.R.</given-names></name><name><surname>Baraki</surname><given-names>B.</given-names></name><name><surname>Shahid</surname><given-names>A.</given-names></name><name><surname>Tadesse</surname><given-names>S.</given-names></name><name><surname>Makonnen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>877</elocation-id><pub-id pub-id-type="doi">10.3390/v11090877</pub-id></element-citation></ref><ref id="B28-pathogens-08-00161"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckton</surname><given-names>A.J.</given-names></name><name><surname>Prabhu</surname><given-names>D.P.</given-names></name><name><surname>Cane</surname><given-names>P.A.</given-names></name><name><surname>Pillay</surname><given-names>D.</given-names></name></person-group><article-title>No evidence for cross-contamination of dried blood spots excised using an office hole-punch for HIV-1 drug resistance genotyping</article-title><source>J. Antimicrob. Chemother.</source><year>2009</year><volume>63</volume><fpage>615</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn518</pub-id><?supplied-pmid 19158111?><pub-id pub-id-type="pmid">19158111</pub-id></element-citation></ref><ref id="B29-pathogens-08-00161"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>C.K.</given-names></name><name><surname>Brumme</surname><given-names>C.J.</given-names></name><name><surname>Liu</surname><given-names>T.F.</given-names></name><name><surname>Chui</surname><given-names>C.K.</given-names></name><name><surname>Chu</surname><given-names>A.L.</given-names></name><name><surname>Wynhoven</surname><given-names>B.</given-names></name><name><surname>Hall</surname><given-names>T.A.</given-names></name><name><surname>Trevino</surname><given-names>C.</given-names></name><name><surname>Shafer</surname><given-names>R.W.</given-names></name><name><surname>Harrigan</surname><given-names>P.R.</given-names></name></person-group><article-title>Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool</article-title><source>J. Clin. Microbiol.</source><year>2012</year><volume>50</volume><fpage>1936</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1128/JCM.06689-11</pub-id><?supplied-pmid 22403431?><pub-id pub-id-type="pmid">22403431</pub-id></element-citation></ref><ref id="B30-pathogens-08-00161"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>D.E.</given-names></name><name><surname>Camacho</surname><given-names>R.J.</given-names></name><name><surname>Otelea</surname><given-names>D.</given-names></name><name><surname>Kuritzkes</surname><given-names>D.R.</given-names></name><name><surname>Fleury</surname><given-names>H.</given-names></name><name><surname>Kiuchi</surname><given-names>M.</given-names></name><name><surname>Heneine</surname><given-names>W.</given-names></name><name><surname>Kantor</surname><given-names>R.</given-names></name><name><surname>Jordan</surname><given-names>M.R.</given-names></name><name><surname>Schapiro</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e4724</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004724</pub-id><pub-id pub-id-type="pmid">19266092</pub-id></element-citation></ref><ref id="B31-pathogens-08-00161"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.F.</given-names></name><name><surname>Shafer</surname><given-names>R.W.</given-names></name></person-group><article-title>Web resources for HIV type 1 genotypic-resistance test interpretation</article-title><source>Clin. Infect. Dis.</source><year>2006</year><volume>42</volume><fpage>1608</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1086/503914</pub-id><?supplied-pmid 16652319?><pub-id pub-id-type="pmid">16652319</pub-id></element-citation></ref><ref id="B32-pathogens-08-00161"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulage</surname><given-names>L.</given-names></name><name><surname>Ssewanyana</surname><given-names>I.</given-names></name><name><surname>Nankabirwa</surname><given-names>V.</given-names></name><name><surname>Nsubuga</surname><given-names>F.</given-names></name><name><surname>Kihembo</surname><given-names>C.</given-names></name><name><surname>Pande</surname><given-names>G.</given-names></name><name><surname>Ario</surname><given-names>A.R.</given-names></name><name><surname>Matovu</surname><given-names>J.K.</given-names></name><name><surname>Wanyenze</surname><given-names>R.K.</given-names></name><name><surname>Kiyaga</surname><given-names>C.</given-names></name></person-group><article-title>Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015</article-title><source>BMC Infect. Dis.</source><year>2017</year><volume>17</volume><elocation-id>326</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-017-2428-3</pub-id><?supplied-pmid 28468608?><pub-id pub-id-type="pmid">28468608</pub-id></element-citation></ref><ref id="B33-pathogens-08-00161"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girum</surname><given-names>T.</given-names></name><name><surname>Wasie</surname><given-names>A.</given-names></name><name><surname>Worku</surname><given-names>A.</given-names></name></person-group><article-title>Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: A time series analysis</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><elocation-id>320</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3214-6</pub-id><pub-id pub-id-type="pmid">29996776</pub-id></element-citation></ref><ref id="B34-pathogens-08-00161"><label>34.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>Eastern Southern Africa: Data</article-title><year>2017</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.unaids.org/en/regionscountries/easternandsouthernafrica">https://www.unaids.org/en/regionscountries/easternandsouthernafrica</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-07-02">(accessed on 2 July 2019)</date-in-citation></element-citation></ref><ref id="B35-pathogens-08-00161"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teasdale</surname><given-names>C.A.</given-names></name><name><surname>Sogaula</surname><given-names>N.</given-names></name><name><surname>Yuengling</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Mutiti</surname><given-names>A.</given-names></name><name><surname>Arpadi</surname><given-names>S.</given-names></name><name><surname>Nxele</surname><given-names>M.</given-names></name><name><surname>Pepeta</surname><given-names>L.</given-names></name><name><surname>Mogashoa</surname><given-names>M.</given-names></name><name><surname>Rivadeneira</surname><given-names>E.D.</given-names></name><etal/></person-group><article-title>HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa</article-title><source>J. Int. AIDS Soc.</source><year>2018</year><volume>21</volume><fpage>e25168</fpage><pub-id pub-id-type="doi">10.1002/jia2.25168</pub-id><pub-id pub-id-type="pmid">30094952</pub-id></element-citation></ref><ref id="B36-pathogens-08-00161"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boender</surname><given-names>T.S.</given-names></name><name><surname>Hoenderboom</surname><given-names>B.M.</given-names></name><name><surname>Sigaloff</surname><given-names>K.C.</given-names></name><name><surname>Hamers</surname><given-names>R.L.</given-names></name><name><surname>Wellington</surname><given-names>M.</given-names></name><name><surname>Shamu</surname><given-names>T.</given-names></name><name><surname>Siwale</surname><given-names>M.</given-names></name><name><surname>Labib Maksimos</surname><given-names>E.E.</given-names></name><name><surname>Nankya</surname><given-names>I.</given-names></name><name><surname>Kityo</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>61</volume><fpage>1749</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1093/cid/civ656</pub-id><pub-id pub-id-type="pmid">26240203</pub-id></element-citation></ref><ref id="B37-pathogens-08-00161"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantor</surname><given-names>R.</given-names></name><name><surname>Smeaton</surname><given-names>L.</given-names></name><name><surname>Vardhanabhuti</surname><given-names>S.</given-names></name><name><surname>Hudelson</surname><given-names>S.E.</given-names></name><name><surname>Wallis</surname><given-names>C.L.</given-names></name><name><surname>Tripathy</surname><given-names>S.</given-names></name><name><surname>Morgado</surname><given-names>M.G.</given-names></name><name><surname>Saravanan</surname><given-names>S.</given-names></name><name><surname>Balakrishnan</surname><given-names>P.</given-names></name><name><surname>Reitsma</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>60</volume><fpage>1541</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1093/cid/civ102</pub-id><?supplied-pmid 25681380?><pub-id pub-id-type="pmid">25681380</pub-id></element-citation></ref><ref id="B38-pathogens-08-00161"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kityo</surname><given-names>C.</given-names></name><name><surname>Boerma</surname><given-names>R.S.</given-names></name><name><surname>Sigaloff</surname><given-names>K.C.E.</given-names></name><name><surname>Kaudha</surname><given-names>E.</given-names></name><name><surname>Calis</surname><given-names>J.C.J.</given-names></name><name><surname>Musiime</surname><given-names>V.</given-names></name><name><surname>Balinda</surname><given-names>S.</given-names></name><name><surname>Nakanjako</surname><given-names>R.</given-names></name><name><surname>Boender</surname><given-names>T.S.</given-names></name><name><surname>Mugyenyi</surname><given-names>P.N.</given-names></name><etal/></person-group><article-title>Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>72</volume><fpage>2587</fpage><lpage>2595</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx188</pub-id><?supplied-pmid 28673027?><pub-id pub-id-type="pmid">28673027</pub-id></element-citation></ref><ref id="B39-pathogens-08-00161"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo-Giang-Huong</surname><given-names>N.</given-names></name><name><surname>Wittkop</surname><given-names>L.</given-names></name><name><surname>Judd</surname><given-names>A.</given-names></name><name><surname>Reiss</surname><given-names>P.</given-names></name><name><surname>Goetghebuer</surname><given-names>T.</given-names></name><name><surname>Duiculescu</surname><given-names>D.</given-names></name><name><surname>Noguera-Julian</surname><given-names>A.</given-names></name><name><surname>Marczynska</surname><given-names>M.</given-names></name><name><surname>Giacquinto</surname><given-names>C.</given-names></name><name><surname>Ene</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children-A EuroCoord-CHAIN-EPPICC joint project</article-title><source>BMC Infect. Dis.</source><year>2016</year><volume>16</volume><elocation-id>654</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1968-2</pub-id><?supplied-pmid 27825316?><pub-id pub-id-type="pmid">27825316</pub-id></element-citation></ref><ref id="B40-pathogens-08-00161"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Xin</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Mammano</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>1408</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1093/jac/dky561</pub-id><?supplied-pmid 30668734?><pub-id pub-id-type="pmid">30668734</pub-id></element-citation></ref><ref id="B41-pathogens-08-00161"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Biagio</surname><given-names>A.</given-names></name><name><surname>Rusconi</surname><given-names>S.</given-names></name><name><surname>Marzocchetti</surname><given-names>A.</given-names></name><name><surname>Signori</surname><given-names>A.</given-names></name><name><surname>Schiavetti</surname><given-names>I.</given-names></name><name><surname>Bruzzone</surname><given-names>B.</given-names></name><name><surname>Monno</surname><given-names>L.</given-names></name><name><surname>Punzi</surname><given-names>G.</given-names></name><name><surname>Colao</surname><given-names>M.G.</given-names></name><name><surname>Penco</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy</article-title><source>J. Med. Virol.</source><year>2014</year><volume>86</volume><fpage>1648</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1002/jmv.24017</pub-id><?supplied-pmid 25042976?><pub-id pub-id-type="pmid">25042976</pub-id></element-citation></ref><ref id="B42-pathogens-08-00161"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paredes</surname><given-names>R.</given-names></name><name><surname>Mocroft</surname><given-names>A.</given-names></name><name><surname>Kirk</surname><given-names>O.</given-names></name><name><surname>Lazzarin</surname><given-names>A.</given-names></name><name><surname>Barton</surname><given-names>S.E.</given-names></name><name><surname>van Lunzen</surname><given-names>J.</given-names></name><name><surname>Katzenstein</surname><given-names>T.L.</given-names></name><name><surname>Antunes</surname><given-names>F.</given-names></name><name><surname>Lundgren</surname><given-names>J.D.</given-names></name><name><surname>Clotet</surname><given-names>B.</given-names></name></person-group><article-title>Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study</article-title><source>Arch. Intern. Med.</source><year>2000</year><volume>160</volume><fpage>1123</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1001/archinte.160.8.1123</pub-id><?supplied-pmid 10789605?><pub-id pub-id-type="pmid">10789605</pub-id></element-citation></ref><ref id="B43-pathogens-08-00161"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derache</surname><given-names>A.</given-names></name><name><surname>Iwuji</surname><given-names>C.C.</given-names></name><name><surname>Danaviah</surname><given-names>S.</given-names></name><name><surname>Giandhari</surname><given-names>J.</given-names></name><name><surname>Marcelin</surname><given-names>A.G.</given-names></name><name><surname>Calvez</surname><given-names>V.</given-names></name><name><surname>de Oliveira</surname><given-names>T.</given-names></name><name><surname>Dabis</surname><given-names>F.</given-names></name><name><surname>Pillay</surname><given-names>D.</given-names></name><name><surname>Gupta</surname><given-names>R.K.</given-names></name></person-group><article-title>Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1093/jac/dky428</pub-id><?supplied-pmid 30380053?><pub-id pub-id-type="pmid">30380053</pub-id></element-citation></ref><ref id="B44-pathogens-08-00161"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruciani</surname><given-names>M.</given-names></name><name><surname>Mengoli</surname><given-names>C.</given-names></name><name><surname>Malena</surname><given-names>M.</given-names></name><name><surname>Serpelloni</surname><given-names>G.</given-names></name><name><surname>Parisi</surname><given-names>S.G.</given-names></name><name><surname>Moyle</surname><given-names>G.</given-names></name><name><surname>Bosco</surname><given-names>O.</given-names></name></person-group><article-title>Virological efficacy of abacavir: Systematic review and meta-analysis</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>3169</fpage><lpage>3180</lpage><pub-id pub-id-type="doi">10.1093/jac/dku279</pub-id><?supplied-pmid 25074854?><pub-id pub-id-type="pmid">25074854</pub-id></element-citation></ref><ref id="B45-pathogens-08-00161"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sax</surname><given-names>P.E.</given-names></name><name><surname>Tierney</surname><given-names>C.</given-names></name><name><surname>Collier</surname><given-names>A.C.</given-names></name><name><surname>Fischl</surname><given-names>M.A.</given-names></name><name><surname>Mollan</surname><given-names>K.</given-names></name><name><surname>Peeples</surname><given-names>L.</given-names></name><name><surname>Godfrey</surname><given-names>C.</given-names></name><name><surname>Jahed</surname><given-names>N.C.</given-names></name><name><surname>Myers</surname><given-names>L.</given-names></name><name><surname>Katzenstein</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>2230</fpage><lpage>2240</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906768</pub-id><pub-id pub-id-type="pmid">19952143</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pathogens-08-00161-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Enrolment and follow up during the first year of treatment. pVL = plasma viral load.</p></caption><graphic xlink:href="pathogens-08-00161-g001"/></fig><fig id="pathogens-08-00161-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>First year virological suppression (&#x0003c;150 copies per mL). <xref ref-type="fig" rid="pathogens-08-00161-f002">Figure 2</xref> represents the time to of virological suppression &#x0003c;150 copies per mL by pretreatment drug resistance status (<bold>A</bold>), baseline viral load (<bold>B</bold>) and NRTI drug type (<bold>C</bold>). PDR&#x02014;Pre-Treatment HIV Drug resistance; AZT&#x02014;Zidovudine; ABC&#x02014;Abacavir; TDF&#x02014;Tenofovir.</p></caption><graphic xlink:href="pathogens-08-00161-g002"/></fig><fig id="pathogens-08-00161-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Virological rebound during the first year of antiretroviral therapy. <xref ref-type="fig" rid="pathogens-08-00161-f003">Figure 3</xref> represents virological rebound stratified by WHO clinical stage (<bold>A</bold>), cART regimen (<bold>B</bold>) and cotrimoxazole preventive therapy (CPT) status (<bold>C</bold>). Stage 1&#x02013;4 represent WHO clinical staging; ABC&#x02013;abacavir; AZT&#x02014;zidovudine; TDF&#x02014;tenofovir; No. at risk&#x02014;Number at risk.</p></caption><graphic xlink:href="pathogens-08-00161-g003"/></fig><table-wrap id="pathogens-08-00161-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-08-00161-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of participants in the cohort (2017&#x02013;2019).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Frequency (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N with Data</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age at enrollment, median (Q1&#x02013;Q3), years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (5&#x02013;12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex, n (%) Male </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63 (56.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any PDR, n (%) Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (11.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tuberculosis, n (%) Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (16.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoniazid preventive therapy, n (%) Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (30.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cotrimozazole preventive therapy, n (%) Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81 (83.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematocrit, median (Q1&#x02013;Q3) in %</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.3 (35.1&#x02013;40.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4+ T cell count, median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">330 (178&#x02013;741)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspartate aminotransferase, median (Q1&#x02013;Q3) units/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (30&#x02013;48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alanine aminotransferase, median (Q1&#x02013;Q3), units/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (20&#x02013;38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Bilirubin, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 (0.4&#x02013;1.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albumin, median (Q1&#x02013;Q3) g/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3.2&#x02013;4.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood urea nitrogen, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (12.1&#x02013;26.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Creatinine, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.4&#x02013;0.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total cholesterol, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120 (96&#x02013;150)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cART Regimen</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">111</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abacavir-based</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (33.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zidovudine-based</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (13.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir-based </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (53.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WHO clinical stage at enrolment </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">110</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stage 1</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (40)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stage 2</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (20.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stage 3</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (30)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (9.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low density lipoprotein, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (32&#x02013;63)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High density lipoprotein, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (38&#x02013;65)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triglyceride, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103 (87&#x02013;151)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weight for age Z score, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;1.2 (&#x02013;2.5&#x02013;(&#x02013;0.6))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Height for age Z score, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;1.4 (&#x02013;2.5&#x02013;(&#x02013;0.6))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body mass index Z score, median (Q1&#x02013;Q3) mg/dL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;1.2 (&#x02013;2.4&#x02013;(&#x02013;0.3))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Log<sub>10</sub> plasma viral load, median (Q1&#x02013;Q3) copies/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 (3.3&#x02013;4.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110</td></tr></tbody></table><table-wrap-foot><fn><p>Q1&#x02013;Q3&#x02014;Interquartile range; n&#x02014;number; PDR&#x02014;Pretreatment drug resistance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pathogens-08-00161-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-08-00161-t002_Table 2</object-id><label>Table 2</label><caption><p>Baseline factors associated with achieving undetectable viremia (pVL &#x0003c; 150 copies per mL) during follow up: univariable and multivariable analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Virological Suppression</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Crude HR (95% CI)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>P</italic> Value</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">aHR (95%CI)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>P</italic> Value </th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Undetectable </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detectable </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age in years:<break/>median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (5&#x02013;12.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (5.5&#x02013;12.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex: N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (60.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (37.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (39.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (62.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 (0.7&#x02013;1.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PDR: N Yes (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (30)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (92.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (70)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 (0.8&#x02013;8.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">11.7 (1.3&#x02013;104.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">TB: N (%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (14)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (18.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80 (86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (81.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.5&#x02013;1.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IPT: N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (30.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No </td><td align="center" valign="middle" rowspan="1" colspan="1">65 (69.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (75)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.5&#x02013;1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (0.1&#x02013;4.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">CPT: N (%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (82.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (85.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">Ref</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (17.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.5&#x02013;1.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HCT in %: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.7 (35.1&#x02013;41.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">36.7 (35.5&#x02013;39)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD4 cells/mm<sup>3</sup> median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">381 (223&#x02013;741)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">217 (178&#x02013;317)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AST in units/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (30&#x02013;46)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (37&#x02013;60)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALT in units/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">26 (18&#x02013;36)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">39 (33&#x02013;42)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bil-T in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.4&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.5&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06 (0.8&#x02013;1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALB in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3.2&#x02013;4.3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3.5&#x02013;4.1)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.8&#x02013;1.3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BUN in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (12&#x02013;24)</td><td align="center" valign="middle" rowspan="1" colspan="1">20.5 (15&#x02013;36)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cr in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.4&#x02013;0.7)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.4&#x02013;0.7)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.3 (0.6&#x02013;2.7)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TChol in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">122 (98&#x02013;152)</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (65&#x02013;142)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">cART Regimen, N (%)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (91.9) </td><td align="center" valign="middle" rowspan="1" colspan="1">3 (8.1) </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (86.7) </td><td align="center" valign="middle" rowspan="1" colspan="1">2 (13.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 (0.6&#x02013;2.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 </td><td align="center" valign="middle" rowspan="1" colspan="1">4.6 (0.1&#x02013;25.8) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.08 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47 (81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (0.9&#x02013;2.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1 (1.0&#x02013;9.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.049</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WHO Stage, N (%) </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (88.4) </td><td align="center" valign="middle" rowspan="1" colspan="1">5 (11.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td><td align="center" valign="middle" rowspan="1" colspan="1">Ref </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (91.1) </td><td align="center" valign="middle" rowspan="1" colspan="1">2 (9.9) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.4&#x02013;1.1) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.14 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (0.1&#x02013;6.0) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.64 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (87.9) </td><td align="center" valign="middle" rowspan="1" colspan="1">4 (12.1) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.4&#x02013;1.1) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.09 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.1&#x02013;8.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.2&#x02013;1.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 (0.1&#x02013;9.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LDL in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (32&#x02013;63)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (35&#x02013;56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.9&#x02013;1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HDL in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">47 (38&#x02013;65)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">45 (33&#x02013;59)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.9 (0.9&#x02013;1)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TG in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">106 (89&#x02013;157)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (69&#x02013;144)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">WAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;2.2&#x02013; (&#x02212;0.5))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;3.4&#x02013; (&#x02212;1.1))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.1)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.6&#x02013;1.6)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.92</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;2.3&#x02013; (&#x02212;0.6))</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;3.0&#x02013; (&#x02212;0.6))</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4 (0.2&#x02013;223)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.0 (&#x02212;2.2&#x02013; (&#x02212;0.1))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;3.1&#x02013; (&#x02212;1.0))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.1 (0.9&#x02013;1.3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">**</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">**</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Log<sub>10</sub>pVL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 (3.2&#x02013;5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3 (4.1&#x02013;5.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 (0.7&#x02013;1.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 (0.6&#x02013;2.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td></tr></tbody></table><table-wrap-foot><fn><p>PDR&#x02014;pretreatment drug resistance; TB&#x02014;Tuberculosis, all forms; IPT&#x02014;isoniazid preventive therapy; CPT&#x02014;co-trimoxazole preventive therapy; HCT&#x02014;hematocrit; AST&#x02014;aspartate transferase; ALT&#x02014;alanine aminotransferase; Bil-T&#x02014;total bilirubin; ALB &#x02013;serum albumin; BUN&#x02014;blood urea nitrogen; LDL&#x02014;low density lipoprotein; TG&#x02014;triglyceride; WAZ&#x02014;weight-for-age Z score; BAZ&#x02014;body mass index-for-age Z score; Log10 pVL&#x02014;baseline viral load (after log transformation); cART&#x02014;combination antiretroviral therapy; HR&#x02014;Hazard ratio; aHR&#x02014;adjusted hazard ratio. ** To avoid collinearity, BAZ (which is a function of weight and height) was excluded from the multivariate model. The following categories were treated as binary variables where &#x0201c;yes&#x0201d; is the reference group&#x02014;PDR, TB, IPT and CPT. The reference groups for categorical variables are indicated on the table. The following were continuous variables, where hazards were defined in terms of unit decrement&#x02014;age, AST, ALT, Albumin, BUN, Creatinine, bilirubin and baseline viral load. The following were continuous variables, where hazards were defined in terms of unit increment&#x02014;CD4 count, hematocrit, total cholesterol, LDL, HDL, TG, WAZ, HAZ and BAZ.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pathogens-08-00161-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pathogens-08-00161-t003_Table 3</object-id><label>Table 3</label><caption><p>Predictors of virological rebound among cART na&#x000ef;ve HIV infected children who achieved virological suppression while on first line antiretroviral therapy (n = 94).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Rebound</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>P</italic> Value </th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">HR (95% CI)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">aHR (95%CI)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>P</italic> Value </th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age in years:<break/>median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (5&#x02013;13)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (7&#x02013;12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.8&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.8&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td></tr><tr><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex: N (%)<break/>Male <break/>Female</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>21 (58.3)<break/>15 (41.7)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>36 (62.1)<break/>22 (37.9)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>0.67</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>1.2 (0.6&#x02013;2.2)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1">PDR: N (%) <break/>Yes <break/>No </td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>2 (18.2)<break/>9 (81.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>1 (3.3)<break/>29 (96.7)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>0.26</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>0.4 (0.1&#x02013;1.9)</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TB: N (%)<break/>Yes <break/>No </td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>32 (88.9)<break/>4 (11.1)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>48 (84.2)<break/>9 (15.8)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>0.93</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>1.0 (0.3&#x02013;2.7)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1">IPT: N (%)<break/>Yes <break/>No </td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>9 (25)<break/>27 (75)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>20 (34.5)<break/>38 (65.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>0.18</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>1.7 (0.8&#x02013;3.6)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>2.2 (0.6&#x02013;7.2)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref <break/>0.22</td></tr><tr><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CPT: N (%)<break/>Yes <break/>No </td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>22(75.9)<break/>7 (24.1)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>43 (86)<break/>7 (14.0)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>0.04</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>0.4 (0.2&#x02013;0.9)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>1.1 (0.2&#x02013;4.2)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref <break/>0.94</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HCT in %: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.4 (32.9&#x02013;41.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.8 (35.9&#x02013;40.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD4 cells/mm<sup>3</sup> median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">447 (223&#x02013;744)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">330 (161&#x02013;741)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AST in units/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (33-&#x02013;54)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (29&#x02013;45)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALT in units/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">27 (17&#x02013;38)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">25 (20&#x02013;34)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bil-T in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8 (0.4&#x02013;1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (0.4&#x02013;1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.5&#x02013;1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ALB in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3&#x02013;4.3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3.8 (3.3&#x02013;4.2)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.6&#x02013;1.4)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BUN in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (12&#x02013;24)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.3 (12&#x02013;25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cr in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.5 (0.4&#x02013;0.6)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.5&#x02013;0.8)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.6 (0.2&#x02013;1.9)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TChol in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">108 (89&#x02013;142)</td><td align="center" valign="middle" rowspan="1" colspan="1">128 (99&#x02013;155)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33</td></tr><tr><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">cART Regimen, N (%)<break/>ABC<break/>AZT<break/>TDF</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>15 (41.7)<break/>5 (13.9)<break/>16 (44.4)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>19 (32.8)<break/>8 (13.8)<break/>31 (53.5)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref<break/>0.25<break/>0.027</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref<break/>0.5 (0.2&#x02013;1.5)<break/>0.4 (0.2&#x02013;0.9)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref<break/>1.0 (0.2&#x02013;4.2)<break/>1.1 (0.3&#x02013;4.1)</td><td align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><break/>Ref<break/>0.96<break/>0.88</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1">WHO Stage, N (%)<break/>1<break/>2<break/>3<break/>4</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>18 (51.4)<break/>6 (17.1)<break/>8 (22.7)<break/>3 (8.6)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>20 (34.5)<break/>15 (25.9)<break/>21 (36.2)<break/>2 (3.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref<break/>0.46<break/>0.37<break/>0.036</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref<break/>0.7 (0.3&#x02013;1.8)<break/>0.7 (0.3&#x02013;1.6)<break/>4.0 (1.1&#x02013;14.3)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref<break/>0.4 (0.1&#x02013;1.6)<break/>0.6 (0.2&#x02013;1.8)<break/>3.6 (0.7&#x02013;18.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><break/>Ref<break/>0.22<break/>0.38<break/>0.13</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LDL in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">45 (25&#x02013;65)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">45 (32&#x02013;63)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (0.9&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDL in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (35&#x02013;64)</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (38&#x02013;65.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TG in mg/dL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">103 (89&#x02013;163)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">106 (92&#x02013;152)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.0 (1.0&#x02013;1.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1 (&#x02212;1.9&#x02013;(&#x02212;0.1))</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2 (&#x02212;2.4&#x02013;(&#x02212;0.6))</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (1.1&#x02013;1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.3 (&#x02212;2.1&#x02013;(&#x02212;0.5))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.5 (&#x02212;2.5&#x02013;(&#x02212;0.6))</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1.1 (1.0&#x02013;1.1)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BAZ in ZS: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;1.9&#x02013;(&#x02212;0.1))</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2 (&#x02212;2.2&#x02013;(&#x02212;0.1))</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2 (1.0&#x02013;1.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Log<sub>10</sub>pVL: median (Q1&#x02013;Q3)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4.1 (3.0&#x02013;5.0)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4.2 (3.3&#x02013;4.8)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.93</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">0.9 (0.6&#x02013;1.2)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>PDR&#x02014;pretreatment drug resistance; TB&#x02014;Tuberculosis, all forms; IPT - isoniazid preventive therapy; CPT&#x02014;co-trimoxazole preventive therapy; HCT&#x02014;hematocrit; AST&#x02014;aspartate transferase; ALT&#x02014;alanine aminotransferase; Bil-T&#x02014;total bilirubin; ALB&#x02014;serum albumin; BUN&#x02014;blood urea nitrogen; LDL&#x02014;low density lipoprotein; TG&#x02014;triglyceride; WAZ&#x02014;weight-for-age Z score; BAZ&#x02014;body mass index-for-age Z score; Log10 pVL&#x02014;baseline viral load (after log transformation); cART&#x02014;combination antiretroviral therapy; HR&#x02014;Hazard ratio; aHR&#x02014;adjusted hazard ratio. ** To avoid collinearity, BAZ (which is a function of weight and height) was excluded from the multivariate model. The following categories were treated as binary variables where &#x0201c;yes&#x0201d; is the reference group&#x02014;PDR, TB, IPT and CPT. The reference groups for categorical variables are indicated on the table. The following were continuous variables, where hazards were defined in terms of unit decrement&#x02014;age, AST, ALT, Albumin, BUN, Creatinine, bilirubin and baseline viral load. The following were continuous variables, where hazards were defined in terms of unit increment&#x02014;CD4 count, hematocrit, total cholesterol, LDL, HDL, TG, WAZ, HAZ and BAZ.</p></fn></table-wrap-foot></table-wrap></floats-group></article>